SLC7A8

Across TCGA pan-cancer cohorts, SLC7A8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC7A8 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLC7A8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC7A8 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where SLC7A8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	III,IV	0.762	0.336	.017	9	view →
HNSC	DFS	Median	II,III,IV	0.993	0.899	.007	7	view →
PDAC	OS	Median	II,III,IV	0.824	0.373	.005	6	view →
LUAD	OS	Tertile	II,III,IV	0.243	0.848	.045	2	view →
UCEC	DFS	Median	All	0.798	1.000	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC7A8–LSCC (DFS)

Open the LSCC breakdown →